Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $6.4400 (2.71%) ($6.4400 - $6.4400) on Tue. Jul. 20, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.53% (three month average) | RSI | 36 | Latest Price | $6.4400(2.71%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | HTBX declines -3.8% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) XBI(54%) ARKG(53%) ARKK(51%) IBUY(48%) ONLN(48%) | Factors Impacting HTBX price | HTBX will decline at least -4.265% in a week (0% probabilities). VIXM(-31%) VXX(-28%) UUP(-14%) TLT(-11%) XLU(-10%) | | | | | Relative Volatility | | | | Market Trend Strength | -4.265% (StdDev 8.53%) | Hourly BBV | 1.8 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-2.51(-138.98%) | Resistance Level | $6.68 | 5 Day Moving Average | $6.29(2.38%) | 10 Day Moving Average | $6.45(-0.16%) | 20 Day Moving Average | $6.68(-3.59%) | To recent high | -40% | To recent low | 10.7% | Market Cap | $709m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |